Clinical Trials Watch2026-W17April 26, 2026

Clinical Trials Watch — 2026-04-26

TITLE: Clinical Trials Watch — Apr 26, 2026: NIAID gene therapy for CGD advances; thin Phase III slate this week

---

Editor's Note

A quiet week on the registry: no Phase III readouts and no outright terminations, though one notable suspension and a heavy NIAID/NIDDK footprint among the active items. Early-phase activity dominates, with a federal gene-therapy program for chronic granulomatous disease and an antiretroviral metabolic study both still enrolling. Detail below, grouped by phase.

Phase I

[NCT05189925] NIAID is recruiting (n=25) for an mRNA-transfected, gp91-enriched granulocyte infusion in chronic granulomatous disease, with feasibility of recruitment, implementation, and manufacturing as the primary endpoint — a foundational readout for whether this CGD gene-correction approach can scale.
[NCT06478420] University of Oxford's COVID-19 Omicron BA.5 dose-finding human challenge study (n=45) is active but no longer recruiting; safety/AE incidence is primary, with the trial positioned to inform future controlled infection models for SARS-CoV-2 variants.
[NCT00862433] A long-completed NIDDK Vitamin E pharmacokinetics study in normal and obese women (n=50) surfaced with activity this week — likely a metadata refresh rather than new science.

Phase II

[NCT05652478] NIAID's Phase 2 randomized ARV metabolic study in healthy volunteers (n=120) is recruiting through Apr 29, measuring 4-week plasma metabolite shifts after antiretroviral initiation — a mechanistic look at the weight-gain signal that has dogged INSTI-based regimens.
[NCT07417553] Beijing Continent Pharmaceutical is recruiting (n=150) for Hydronidone capsules in HBV-related liver fibrosis, with AE/SAE incidence as primary — a safety-led Phase 2 in an indication where antifibrotic candidates have repeatedly stumbled.

Phase III

No Phase III activity registered this cycle. Watch this space.

Phase IV / Observational / Device

[NCT07388537] NIDDK is launching a 1,000-patient natural-history evaluation of the clinical spectrum of diabetes and obesity in youth and adults (start Apr 29) — sample/data collection only, but a likely substrate for downstream interventional arms.
[NCT00594672] The AREDS follow-up cohort at the National Eye Institute remains active-not-recruiting, continuing long-tail ocular outcomes capture in age-related macular degeneration and cataract.
[NCT07550543] Romania's Techirghiol sanatorium is recruiting (n=60) for PEMF therapy in shoulder tendinopathy, with VAS pain as primary — small device-rehab study, modest read-through.
[NCT07431034] A 200-patient internet-CBT-for-insomnia trial in Persian-speaking adults is active-not-recruiting; ISI score is primary. Single-investigator sponsorship limits broader signal.

Suspensions & Flags

⚠️ [NCT04872309] Sheffield Teaching Hospitals' multi-nuclear MR lung imaging study in asthma and COPD (n=160) is SUSPENDED — the COVID arm completed and the remainder is paused pending new funding. Not a safety stop, but worth tracking for restart or quiet closure.

Bottom Line

The CGD ex-vivo mRNA program (NCT05189925) and the NIAID ARV metabolic study (NCT05652478) are the two items with genuine mechanistic upside this week. Everything else is incremental or administrative. No Phase III readouts; no terminations.